tubacin has been researched along with Thrombocytopenia* in 1 studies
1 other study(ies) available for tubacin and Thrombocytopenia
| Article | Year |
|---|---|
Compounds targeting class II histone deacetylases do not cause panHDACI-associated impairment of megakaryocyte differentiation.
Histone deacetylase inhibitors (HDACIs) have demonstrated effectiveness against lymphomas and myelomas in clinical practice. However, common to all currently approved broad-acting HDACIs (panHDACIs) is dose-limiting thrombocytopenia, which has prevented wider use in cancer therapy. Using CD34 Topics: Anilides; Antigens, CD34; Cell Differentiation; Cell Line, Tumor; GATA1 Transcription Factor; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Megakaryocytes; Proteasome Endopeptidase Complex; Proteolysis; Thrombocytopenia | 2019 |